{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T14:35:55Z","timestamp":1780756555510,"version":"3.54.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,5]]},"DOI":"10.7759\/cureus.37172","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T18:55:06Z","timestamp":1680720906000},"source":"Crossref","is-referenced-by-count":6,"title":["Focal Cryoablation of the Prostate: Primary Treatment in 163 Patients With Localized Prostate Cancer"],"prefix":"10.7759","author":[{"given":"Anwar","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansar U","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Siref","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Feloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Cryosurgical treatment of the prostate","volume":"3","author":"Gonder MJ","year":"1966","unstructured":"Gonder MJ, Soanes WA, Shulman S. Cryosurgical treatment of the prostate. Invest Urol. 1966, 3:372-378.","journal-title":"Invest Urol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-4295(02)01679-5","article-title":"Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery","volume":"60","author":"Robinson JW","year":"2002","unstructured":"Robinson JW, Donnelly BJ, Saliken JC, Weber BA, Ernst S, Rewcastle JC. Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. Urology. 2002, 60:12-18. 10.1016\/s0090-4295(02)01679-5","journal-title":"Urology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-4295(02)01678-3","article-title":"Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer","volume":"60","author":"Bahn DK","year":"2002","unstructured":"Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology. 2002, 60:3-11. 10.1016\/s0090-4295(02)01678-3","journal-title":"Urology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.08.085","article-title":"Focal therapy eligibility determined by magnetic resonance imaging\/ultrasound fusion biopsy","volume":"199","author":"Nassiri N","year":"2018","unstructured":"Nassiri N, Chang E, Lieu P, et al.. Focal therapy eligibility determined by magnetic resonance imaging\/ultrasound fusion biopsy. J Urol. 2018, 199:453-458. 10.1016\/j.juro.2017.08.085","journal-title":"J Urol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach M 3rd","year":"2006","unstructured":"Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006, 65:965-974. 10.1016\/j.ijrobp.2006.04.029","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199104253241702","article-title":"Measurement of prostate-specific antigen in serum as a screening test for prostate cancer","volume":"324","author":"Catalona WJ","year":"1991","unstructured":"Catalona WJ, Smith DS, Ratliff TL, et al.. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991, 324:1156-1161. 10.1056\/NEJM199104253241702","journal-title":"N Engl J Med"},{"key":"ref7","article-title":"Contemporary role of the Decipher\u00ae test in prostate cancer management: current practice and future perspectives","volume":"18","author":"Dalela D","year":"2016","unstructured":"Dalela D, L\u00f6ppenberg B, Sood A, Sammon J, Abdollah F. Contemporary role of the Decipher\u00ae test in prostate cancer management: current practice and future perspectives. Rev Urol. 2016, 18:1-9.","journal-title":"Rev Urol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management","volume":"208","author":"Eastham JA","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, et al.. Clinically localized prostate cancer: AUA\/ASTRO guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol. 2022, 208:10-18. 10.1097\/JU.0000000000002757","journal-title":"J Urol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/153303460400300303","article-title":"In treating localized prostate cancer the efficacy of cryoablation is independent of DNA ploidy type","volume":"3","author":"Bahn DK","year":"2004","unstructured":"Bahn DK, Silverman P, Lee F Sr, Badalament R, Bahn ED, Rewcastle JC. In treating localized prostate cancer the efficacy of cryoablation is independent of DNA ploidy type. Technol Cancer Res Treat. 2004, 3:253-257. 10.1177\/153303460400300303","journal-title":"Technol Cancer Res Treat"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/0970-1591.44254","article-title":"Primary cryoablation for Gleason 8, 9, or 10 localized prostate cancer: Biochemical and local control outcomes from the Cryo OnLine database registry","volume":"24","author":"Jones JS","year":"2008","unstructured":"Jones JS, Rewcastle JC. Primary cryoablation for Gleason 8, 9, or 10 localized prostate cancer: Biochemical and local control outcomes from the Cryo OnLine database registry. Indian J Urol. 2008, 24:490-493. 10.4103\/0970-1591.44254","journal-title":"Indian J Urol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000456","article-title":"Hemigland cryoablation of localized low, intermediate and high risk prostate cancer: oncologic and functional outcomes at 5 years","volume":"202","author":"Oishi M","year":"2019","unstructured":"Oishi M, Gill IS, Tafuri A, et al.. Hemigland cryoablation of localized low, intermediate and high risk prostate cancer: oncologic and functional outcomes at 5 years. J Urol. 2019, 202:1188-1198. 10.1097\/JU.0000000000000456","journal-title":"J Urol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.06.006","article-title":"A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer","volume":"74","author":"Guillaumier S","year":"2018","unstructured":"Guillaumier S, Peters M, Arya M, et al.. A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer. Eur Urol. 2018, 74:422-429. 10.1016\/j.eururo.2018.06.006","journal-title":"Eur Urol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.102","article-title":"Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook experience","volume":"196","author":"Musunuru HB","year":"2016","unstructured":"Musunuru HB, Yamamoto T, Klotz L, et al.. Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook experience. J Urol. 2016, 196:1651-1658. 10.1016\/j.juro.2016.06.102","journal-title":"J Urol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30661-1","article-title":"Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial","volume":"18","author":"Azzouzi AR","year":"2017","unstructured":"Azzouzi AR, Vincendeau S, Barret E, et al.. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol. 2017, 18:181-191. 10.1016\/S1470-2045(16)30661-1","journal-title":"Lancet Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-3942-9","article-title":"Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation","volume":"22","author":"Liu YY","year":"2015","unstructured":"Liu YY, Chiang PH, Chuang YC, Lee WC, Cheng YT, Wang HJ. Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation. Ann Surg Oncol. 2015, 22:1612-1617. 10.1245\/s10434-014-3942-9","journal-title":"Ann Surg Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30665","article-title":"Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: interim results from the Multicenter Prospective PRO-IMPACT study","volume":"123","author":"Gore JL","year":"2017","unstructured":"Gore JL, du Plessis M, Santiago-Jim\u00e9nez M, et al.. Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: interim results from the Multicenter Prospective PRO-IMPACT study. Cancer. 2017, 123:2850-2859. 10.1002\/cncr.30665","journal-title":"Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.03.006","article-title":"Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years","volume":"62","author":"Bahn D","year":"2012","unstructured":"Bahn D, de Castro Abreu AL, Gill IS, et al.. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol. 2012, 62:55-63. 10.1016\/j.eururo.2012.03.006","journal-title":"Eur Urol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/130150-focal-cryoablation-of-the-prostate-primary-treatment-in-163-patients-with-localized-prostate-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:57:02Z","timestamp":1707508622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/130150-focal-cryoablation-of-the-prostate-primary-treatment-in-163-patients-with-localized-prostate-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.37172","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,5]]}}}